Get the Stockscreener App
3.47
2.66%
0.09
Sonnet Biotherapeutics Holdings Inc stock is traded at $3.47, with a volume of 266.47K.
It is up +2.66% in the last 24 hours and down -32.62% over the past month.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
See More
Previous Close:
$3.38
Open:
$3.29
24h Volume:
266.47K
Relative Volume:
0.07
Market Cap:
$23.44M
Revenue:
$129.20K
Net Income/Loss:
$-7.44M
P/E Ratio:
-0.3101
EPS:
-11.19
Net Cash Flow:
$-8.62M
1W Performance:
-1.98%
1M Performance:
-32.62%
6M Performance:
+140.97%
1Y Performance:
-38.14%
1-Day Range:
$3.24
$3.52
1-Week Range:
$2.9906
$3.61
52-Week Range:
$1.08
$19.30
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile
Name
Sonnet Biotherapeutics Holdings Inc
Sector
Industry
Phone
609-375-2227
Address
100 OVERLOOK CENTER, PRINCETON, NJ
Compare SONN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SONN
Sonnet Biotherapeutics Holdings Inc
|
3.47 | 20.98M | 129.20K | -7.44M | -8.62M | -11.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Latest News
Analysts Spot Bullish Divergence in Sonnet BioTherapeutics Holdings Inc.Portfolio Growth Summary & Verified Chart Pattern Signals - newsyoung.net
Why Sonnet BioTherapeutics Holdings Inc. stock attracts strong analyst attentionJuly 2025 Trade Ideas & Daily Stock Momentum Reports - Newser
Can trapped investors hope for a rebound in Sonnet BioTherapeutics Holdings Inc.Portfolio Growth Summary & Low Risk Growth Stock Ideas - Newser
Should you wait for a breakout in Sonnet BioTherapeutics Holdings Inc.Quarterly Portfolio Report & Low Volatility Stock Recommendations - Newser
Using RSI to spot recovery in Sonnet BioTherapeutics Holdings Inc.New Guidance & Safe Entry Point Alerts - Newser
Sonnet BioTherapeutics Holdings Inc. stock prediction for this weekMarket Sentiment Report & Daily Volume Surge Signals - Newser
Smart tools for monitoring Sonnet BioTherapeutics Holdings Inc.’s price actionWeekly Loss Report & AI Driven Price Predictions - Newser
Is Sonnet BioTherapeutics Holdings Inc. building a consolidation baseGDP Growth & Technical Entry and Exit Alerts - Newser
Real time social sentiment graph for Sonnet BioTherapeutics Holdings Inc.Bull Run & Risk Managed Trade Strategies - Newser
Is Sonnet BioTherapeutics Holdings Inc. stock bottoming out2025 Breakouts & Breakdowns & Advanced Technical Signal Analysis - Newser
Sonnet BioTherapeutics Holdings Inc. Stock Performance After Earnings: Historical Insights2025 Market Overview & Fast Moving Trade Plans - Newser
Real time alert setup for Sonnet BioTherapeutics Holdings Inc. performance2025 Volume Leaders & Daily Price Action Insights - Newser
Is this a good reentry point in Sonnet BioTherapeutics Holdings Inc.2025 Historical Comparison & Weekly Top Gainers Trade List - Newser
Sonnet BioTherapeutics Holdings Inc. stock daily chart insights2025 Major Catalysts & AI Powered Buy/Sell Recommendations - Newser
Analyzing net buyer seller activity in Sonnet BioTherapeutics Holdings Inc.Options Play & Daily Profit Focused Stock Screening - Newser
Published on: 2025-08-16 23:11:22 - Newser
How to monitor Sonnet BioTherapeutics Holdings Inc. with trend dashboardsForecast Cut & Free Technical Pattern Based Buy Signals - Newser
What is the PEG ratio of Sonnet BioTherapeutics Holdings Inc.2025 Key Lessons & Reliable Trade Execution Plans - 선데이타임즈
Sonnet Biotherapeutics Faces Earnings Volatility with New HYPE Treasury Strategy and Accounting Standards - MSN
Sonnet Biotherapeutics Holdings Faces Earnings Volatility with New HYPE Treasury Strategy and Accounting Standards - AInvest
Sonnet Biotherapeutics Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Sonnet Releases Virtual Investor What This Means Segment - MarketScreener
Pilot Killed In NJ Crash Was CEO Of Cancer-Focused Biotech Company - MSN
Sonnet Releases Virtual Investor 'What This Means' Segment - The Manila Times
Sonnet Releases Virtual Investor "What This Means" Segment - GlobeNewswire
Breakthrough: Sonnet's Ovarian Cancer Drug Achieves 67% Response Rate, Trial Expands with Higher Dose - Stock Titan
Why Did Sonnet BioTherapeutics Holdings Soar 11.49%? - AInvest
Sonnet BioTherapeutics Holdings Inc. Added to High Probability Setup ListStock Portfolio Allocation Guidance for Volatile Markets - beatles.ru
Short Interest Drops in Sonnet BioTherapeutics Holdings Inc. After RallyOptimized Watchlist With Daily Adjustments Launched - beatles.ru
Sonnet Biotherapeutics Holdings Inc expected to post a loss of 49 cents a shareEarnings Preview - TradingView
This Cancer Biotech Company Is Making a Big Bet on the HYPE Crypto. Should You Buy Its Stock Here? - Yahoo Finance
Sonnet BioTherapeutics Expands Clinical Study of SON-1010 in Combination with Atezolizumab for Advanced Platinum-Resistant Ovarian Cancer - Quiver Quantitative
Sonnet BioTherapeutics Expands Clinical Evaluation of - GlobeNewswire
Cancer Drug Shows 66% Response Rate in Ovarian Cancer Trial: Sonnet BioTherapeutics Advances to Higher Dose - Stock Titan
Live Chart Scan Detects Wedge Pattern in Sonnet BioTherapeutics Holdings Inc.Swing Trade Entry With Volume Triggers Released - beatles.ru
Is Sonnet BioTherapeutics Holdings Inc. stock overvalued or undervaluedRecord-breaking capital gains - Jammu Links News
What is the dividend policy of Sonnet BioTherapeutics Holdings Inc. stockBuild wealth faster with disciplined trading - Jammu Links News
Why is Sonnet BioTherapeutics Holdings Inc. stock attracting strong analyst attentionCapitalize on proven investment strategies - Jammu Links News
How strong is Sonnet BioTherapeutics Holdings Inc. company’s balance sheetFree Daily Trading Room Entry - Jammu Links News
What analysts say about Sonnet BioTherapeutics Holdings Inc. stockIdentify undervalued stocks poised to rally - Jammu Links News
What are the latest earnings results for Sonnet BioTherapeutics Holdings Inc.Fastest return on investment - Jammu Links News
What institutional investors are buying Sonnet BioTherapeutics Holdings Inc. stockExpert guidance for superior capital growth - Jammu Links News
What is the risk reward ratio of investing in Sonnet BioTherapeutics Holdings Inc. stockTransform your portfolio with high-yield stocks - Jammu Links News
What drives Sonnet BioTherapeutics Holdings Inc. stock priceStay ahead with daily market updates - Jammu Links News
What catalysts could drive Sonnet BioTherapeutics Holdings Inc. stock higher in 2025Dynamic profit expansion - Jammu Links News
Is it the right time to buy Sonnet BioTherapeutics Holdings Inc. stockHigh-velocity gains - Jammu Links News
Sonnet BioTherapeutics Appoints Interim CEO Raghu Rao - The Globe and Mail
Sonnet BioTherapeutics enters employment agreement with interim CEO Raghu Rao - Investing.com Australia
Is Sonnet BioTherapeutics Holdings Inc. a growth stock or a value stockBest Dividend Insights For Fast Growth - Jammu Links News
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):